The most effective way to speed up prior authorization for medication is to submit a complete, payer-specific documentation package on the first attempt.
Incomplete submissions are the primary driver of multi-round reviews, and each additional review round adds days to resolution. The tactics below address every layer of that delay.
A 2026 JAMA study found that only 35% of initially rejected medication prior authorizations are processed in one day. Multiple review rounds are the primary driver of delay.
That gap is not random. It is operational. And it is largely preventable.
This guide covers concrete, evidence-backed steps to speed up prior authorization for medication, starting with the first submission. Here is what you will find:
- How to submit complete documentation on the first attempt
- When and why to use electronic prior authorization instead of fax
- Which payer and federal reform changes are already shortening timelines
- How to navigate step therapy requirements and quantity limits
- How to appeal denials with targeted evidence
Why do medication prior authorizations take so long?
Medication prior authorizations take so long primarily because of incomplete first submissions that trigger multiple review rounds.
Also, fax-based workflows that lack structured feedback, and payer-specific criteria that are difficult to interpret without a dedicated reference. Each of those root causes is addressable.
The 2026 JAMA study shows that 65% of rejected medication PAs take a median of 6 days to resolve.
The AMA 2025 Prior Authorization Physician Survey found that practices spend 13 hours per week on prior authorization tasks.
Yet only 35% of medical PA transactions are fully electronic, per the 2024 CAQH Index. The root causes are consistent:
- Fax-based workflow
- Multiple review rounds
- Incomplete submissions
- Payer criteria that are difficult to interpret without a dedicated guide
Each tactic below targets one of these levers.
How can you submit a complete PA on the first attempt?
Submit a complete PA on the first attempt by using a standardized checklist that covers every required element:
- Drug details
- Diagnosis codes
- Step therapy history
- Prescriber information
- Supporting clinical data
- Medical necessity rationale
A complete first submission eliminates the information requests that trigger second review rounds. This is the single highest-impact change your practice can make.
A PA that contains everything a reviewer needs moves straight through. One that is missing a lab result, a therapy history date, or an ICD-10 code comes back, and that second round costs you days.
The fastest PA is the one that never triggers a second review round.
Using a complete prior authorization checklist on every first submission is not a best practice. It is the primary operational lever for faster approvals.
First-submission documentation checklist
Here are all the required elements and what to include:
| Required element | What to include |
| Diagnosis | Primary ICD-10 code plus any supporting secondary codes |
| Drug details | Name, dose, route of administration, quantity, days’ supply |
| Medical necessity | Clinical rationale tied directly to the stated diagnosis |
| Step therapy history | Prior medications tried, doses, dates, and documented failure reason |
| Supporting clinical data | Relevant labs, imaging results, specialist notes |
| Prescription type | New start or refill; if refill, include previous authorization number |
| Prescriber information | NPI, DEA number if applicable, direct contact details |
Days’ supply: Start with what the plan allows
JAMA data shows that requests for more than 30 days’ supply had a lower approval rate, 50% versus 55% for shorter supplies.
When clinically appropriate, start with the plan-allowed quantity. Save the extended-supply request for a renewal once you have an established approval history with that payer.
Refills vs. new starts: Different packets, different tactics
JAMA data shows refills are approved at a higher rate, 72% versus 51% for new starts. Same-day processing is lower for refills, however: 24% versus 37%.
Reviewers treat continuation therapy with more scrutiny on justification, even when approval rates are higher. For refill submissions, always include:
- Original therapy start date
- Duration of uninterrupted use
- Previous authorization number, if available
- Explicit statement of harm risk from interruption
- Documented clinical stability on the current regimen
Should you use electronic prior authorization instead of fax?
Yes, every time it is available.
Electronic prior authorization eliminates the transcription errors, missing fields, and feedback delays that make fax-based submissions the slowest point in the PA workflow.
The speed and accuracy difference is not marginal, it is structural.
The 2024 CAQH Index calculated that electronic prior authorization saves an average of 14 minutes per transaction compared to manual methods.
Across a full practice volume, that adds up to $515 million in annual industry-wide savings.
The speed numbers are concrete. CVS Caremark has reported a median approval time of 18 seconds for 83 or more medications processed through its automated PA system.
That reflects best-case prior authorization automation but it demonstrates the ceiling that structured, electronic data can reach compared to unstructured fax documents.
Beyond speed, ePA eliminates transcription errors that consistently drive denials.
Drug name, dose, and diagnosis code flow directly from the EHR in a standardized format. There is no handwriting to misread and no field inadvertently left blank.
One upstream step worth adding — use a real-time benefit check at the point of prescribing. Several EHR and e-prescribing platforms now surface PA requirements before you submit a request.
Knowing a PA is required before writing the prescription gives you time to prepare documentation, or to identify an equivalent drug that does not trigger one.
How do you avoid triggering prior authorization in the first place?
The most reliable way to avoid triggering prior authorization is to prescribe formulary-preferred or generic alternatives when clinically equivalent.
Most PA requirements are tied to specific drug tiers, prescribing at the right tier eliminates the requirement before it starts.
The fastest prior authorization for medication is the one you never have to file. Formulary awareness is the most direct way to reduce PA volume before it starts.
The AMA 2025 survey found that 63% of physicians report difficulty determining whether a PA is required for a specific drug. That uncertainty is costly.
When a practice submits a PA for a medication that could be replaced by a formulary-preferred alternative, it adds unnecessary administrative burden and delays patient access.
Practical steps to reduce unnecessary PA volume:
| Strategy | What to do | How it helps |
| Check formulary | Most major payers publish PA drug lists. Keep a current version accessible at the point of care. | Helps identify prior authorization requirements before prescribing. |
| Prescribe generics | Use Tier 1 and Tier 2 medications when clinically appropriate. | These are far less likely to require PA than brand-name or specialty drugs. |
| Know step therapy | Review whether the drug requires documented failure of a first-line agent. Have documentation ready, or reconsider the prescribing order when clinically acceptable. | Reduces delays caused by missing step-therapy evidence. |
| Verify benefits | Use clearinghouses or pharmacy benefit managers that offer real-time PA checks within the prescribing workflow. | Confirms coverage and PA needs before the prescription reaches the pharmacy. |
When a patient has already completed the required step therapy sequence, file a step therapy exception request with clear documentation of each prior trial.
Federal law and most state statutes require payers to provide a formal exception process. Knowing how to use it correctly is as important as knowing when to invoke it.
What should you do when a medication PA is denied?
When a medication PA is denied, read the denial reason first, then build your appeal response to address only that stated reason.
Resubmitting the entire case without targeting the specific denial basis is the most common appeal mistake, and the most avoidable.
A denial is not a final answer. The AMA 2025 survey found that only 21% of physicians always file a prior authorization denial appeal.
The gap between those two numbers represents a substantial volume of approvals being left on the table. A structured appeal workflow consistently outperforms reactive submissions. Build yours around three components:
- Templated letters
- Assigned ownership
- Tracked timelines
You can follow this sequence:
What are the latest federal and payer changes speeding up medication PA?
The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), effective January 2026, requires covered plans to respond within 72 hours for urgent requests and 7 calendar days for non-urgent ones.
Several major payers have already moved ahead of these mandates voluntarily.
Regulatory momentum is reshaping PA timelines. Knowing the CMS prior authorization rule 2026 and related payer commitments help you set accurate expectations and identify which payers are already ahead of the compliance curve.
Check whether your specific payer has already reduced PA requirements or adopted shorter review timelines ahead of the dates below. Several have moved proactively.
Key regulatory and payer timelines
Here are some timelines to keep in mind:
Review your specific payer contracts to determine whether they have voluntarily adopted similar timelines or whether your state has set additional requirements.
The AHIP 90-day continuity commitment is particularly relevant for patients transitioning between health plans mid-treatment.
If a patient’s insurer changes while a therapy is active, the prior authorization should carry forward for at least 90 days. Document the previous approval number and reference it explicitly in any transition PA request.
Prior Authorization should not slow down patient care or revenue
Medication prior authorization moves faster when every submission is complete, payer-specific, and followed through without delay.
MedHeave manages the full prior authorization workflow for medical practices, from documentation review and submission to payer follow-up, appeals, and approval tracking.
- PA tracking tied to billing readiness
- Timely follow-up on stalled requests
- Complete PA packets from the first submission
- Targeted appeal support for denials
- Payer-specific checks before filing
Delayed approvals create delayed treatment and delayed revenue. Talk to MedHeave about building a prior authorization process that moves cleanly from request to approval.
Frequently Asked Questions
Here are some commonly asked questions on this topic:
It varies by payer, drug class, and submission completeness. The 2026 JAMA study shows 35% of PA decisions are made same-day. For requests that go into a second review round, the median rises to 6 days. The Arthritis Foundation reports a 3-day average across payers, with 31% of patients waiting more than a week. Under the CMS prior authorization rule 2026, covered plans must respond within 72 hours for urgent requests and 7 calendar days for non-urgent ones.
Yes. When delay could seriously harm the patient, rapid disease progression, hospitalization risk, or disruption of a stable medication regimen, you can request expedited prior authorization. Include a specific clinical rationale for urgency in the submission. Under the CMS final rule, covered plans must respond to urgent requests within 72 hours.
The most common causes of prior authorization delay are: incomplete documentation at first submission, triggering an information request; multiple review rounds resetting the clock; fax-based submission with no structured feedback; and unclear or payer-specific criteria. Auditing your denial and delay reasons over a rolling 90-day period will identify which driver is most prevalent in your practice.
The Arthritis Foundation data puts the average at 3 days, with 31% of patients waiting over a week. JAMA data shows wide variation based on submission completeness, 35% of requests receive same-day decisions when documentation is complete, while incomplete submissions can extend to a median of 6 days across multiple review cycles. Practices using electronic prior authorization with complete first-submission documentation consistently track below the industry average on how long does prior authorization take.
